N/A
N=286
A New and Innovative Method for CO2 Removal in Anesthetic Circuits
Anesthesia
Bottom Line
View on ClinicalTrials.gov: NCT03014336 ↗Enrolled (actual)
286
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: End-tidal CO2 Concentration (%) — 5.069; 5.096 % end-tidal CO2
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- memsorb (Device)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- DMF Medical Incorporated
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY End-tidal CO2 Concentration (%) |
5.069; 5.096 | — |
Summary
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
Eligibility Criteria
Inclusion Criteria
- American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
- English-speaking patients
Exclusion Criteria
- Self-reported as pregnant
- American Society of Anesthesiologists Physical Status Class IV (high risk patient)
- Patients scheduled for emergency surgery
- Documented respiratory disease, including COPD and severe asthma
- Documented elevated pressure in the brain (intra cranial pressure, ICP)
Data sourced from ClinicalTrials.gov (NCT03014336). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.